Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of bortezomib combined with rituximab for relapsed or refractory B-cell non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: University of Virginia | Conditions: Lymphoma | Phase 2 | Status: TERMINATED